List of pathologists

LifeLabs Promotes Dr. Cathy Ross to Vice President of Medical and Quality Affairs, Driving Growth and Quality Healthcare Services Nationwide

Retrieved on: 
Wednesday, May 3, 2023
Abstract, Medicine, Royal college, Master of Science in Quality Management and Analytics, Cancer Care Ontario, Schulich School of Medicine & Dentistry, Safety, Physician, Business, CFB Toronto, Anatomical pathology, Quality, Royal College of Physicians and Surgeons of Canada, McMaster University, Pathology, Surgeon, Master, Quality assurance, Growth, Schulich School of Business, Hospital Insurance and Diagnostic Services Act, Patient safety, Complex, Medical device, Management, Science, List of pathologists

Dr. Ross's appointment marks an exciting new chapter in LifeLabs' growth story and underscores its commitment to building strong relationships and delivering high-quality healthcare services.

Key Points: 
  • Dr. Ross's appointment marks an exciting new chapter in LifeLabs' growth story and underscores its commitment to building strong relationships and delivering high-quality healthcare services.
  • "We are thrilled to have Dr. Cathy Ross leading our Med-Sci and Quality teams," said Charles Brown, CEO of LifeLabs.
  • "During her time with LifeLabs, Dr. Ross has built trusted relationships internally and externally and clearly understands LifeLabs' customers' needs.
  • As Vice President of Medical and Quality Affairs, Dr. Ross will oversee LifeLabs' Medical Science and Quality teams nationwide, playing a critical role in its operations and supporting LifeLabs' strategic objectives.

GC LabTech Launches Partnership with 1health.io to Deploy Innovative Lab Tests Direct-to-Consumer

Retrieved on: 
Monday, October 24, 2022
Health, Technology, Infectious Diseases, Other Science, Software, Science, CAP, ISO, Blood, CLIA, Efficiency, Public health, List of pathologists, Laboratory, E-commerce, California Department, CAGR, Korean Ministry of Culture, GC, Research, College of American Pathologists, South Dakota State Test of Educational Progress, Partnership, Technology, International Organization (journal), Transparency (market), Starbucks, Health, Association, United, Plasma, FDA, Medical device, Fine chemical, Food

GC LabTech, a subsidiary of GC Biopharma of South Korea, and a CAP & ISO accredited, FDA-registered specialty laboratory with life-saving plasma tests, selects 1health.io, an industry-leading software company revolutionizing the way laboratories expand testing into the at-home markets, to deliver its innovative new lab tests direct-to-consumers.

Key Points: 
  • GC LabTech, a subsidiary of GC Biopharma of South Korea, and a CAP & ISO accredited, FDA-registered specialty laboratory with life-saving plasma tests, selects 1health.io, an industry-leading software company revolutionizing the way laboratories expand testing into the at-home markets, to deliver its innovative new lab tests direct-to-consumers.
  • The new partnership between 1health and GC LabTech enables GC LabTech to sell its innovative new health and wellness tests into the $1 billion direct-to-consumer lab testing market, which is forecasted to grow to $8.8 billion by 2031 according to research group Transparency Marketing in its report North America Direct-to-Consumer Laboratory Testing Market Insights, 2021-2031 published in Q1 2022.
  • Known for its highly accurate, optimized efficiency, and fast turnaround service, GC LabTech is applying its high-performance lab testing capabilities to the direct-to-consumer segment.
  • Previously, GC Lab Tech had explored the direct-to-consumer market but found it did not have the front-end or back-end infrastructure to launch the tests to the consumer.

Naveris Collaborators Present Award-winning Abstract at ASTRO 2022 on Potential of NavDx to Inform Treatment Strategies in HPV-driven Cancers

Retrieved on: 
Monday, October 24, 2022
Biotechnology, Health, Oncology, LinkedIn, Papilloma, CLIA, College of American Pathologists, Risk, Mayo Clinic, Disease, American Society for Radiation Oncology, Head, Radiation, DART, TTMV, List of pathologists, Society, Patient, Biotechnology, Twitter, Annual general meeting, Cancer, III, DRS, MRD, Radiation therapy, ASTRO, Progression-free survival, Toxicity, CEO, College, Recurrence, HPV, OPSCC, DNA, Medical imaging, Pharmaceutical industry, Vaccine, Raoul de Navery

radiation oncologist, Mayo Clinic, and first author of the study, was honored with the ASTRO Basic/Translational Science Award for this work.

Key Points: 
  • radiation oncologist, Mayo Clinic, and first author of the study, was honored with the ASTRO Basic/Translational Science Award for this work.
  • The presence of MRD, both in the post-operative setting and at 3 months post-treatment, was significantly associated with shorter progression-free survival.
  • Results from the MC1675 trial were initially presented at the ASTRO 2021 annual meeting and follow-up is ongoing.
  • More information on Naveris and NavDx can be found at booth #2348, or look for highlights from #ASTRO22 Twitter and LinkedIn .

Apollo's Digital Pathology Solution arcc® Implemented at Temple University Health System

Retrieved on: 
Tuesday, October 25, 2022
Enterprise imaging, Apollo, Science Publishing Group, Temple Health, Digital pathology, Pathology, List of pathologists, Hospital, Medical laboratory, Acquisition, CEO, Enterprise, Digital, AVP, Medical imaging

TYSONS, Va., Oct. 25, 2022 /PRNewswire-PRWeb/ -- Apollo, the leading provider of enterprise imaging and clinical multimedia management solutions, today announced that it has successfully deployed its Digital Pathology and enterprise imaging solution, arcc®, to support the management of Digital Pathology at Temple University Health System.

Key Points: 
  • TYSONS, Va., Oct. 25, 2022 /PRNewswire-PRWeb/ -- Apollo, the leading provider of enterprise imaging and clinical multimedia management solutions, today announced that it has successfully deployed its Digital Pathology and enterprise imaging solution, arcc, to support the management of Digital Pathology at Temple University Health System.
  • arcc for Pathology includes a focused workflow solution for Pathology to centrally and securely manage pathology images and their associated metadata.
  • "arcc for Pathology provides Temple Health with a solution that increases laboratory productivity and offers our Pathologists a high degree of flexibility in how Pathology imaging and related case information are managed and viewed enterprise-wide," said Christopher Burks, AVP, Laboratory Operations, Pathology & Laboratory Medicine, at Temple Health.
  • "We are honored and excited to be implemented at Temple Health with our arcc for Pathology solution," said Mark Newburger, Apollo President and CEO.

Nucleix Receives CAP Accreditation and CLIA Certification for its San Diego Clinical Laboratory

Retrieved on: 
Wednesday, October 19, 2022
Biotechnology, Medical Devices, Hospitals, Health, Oncology, CAP, Clinical Laboratory Improvement Amendments, Physician, U.S. Department of Commerce Office of Security, California Department of Public Health, Urinary bladder, CLIA, Accreditation, Centers for Medicare & Medicaid Services, Office of Inspector General, U.S. Department of Health and Human Services, Public health, Accreditation Committee of Cambodia, California Department, List of pathologists, Laboratory, Patient, Bladder cancer, CMS, Research, Program, Lung, PCR, Cancer, Certification, Technology, Company, Medicare, NGS, Safety, College, Marie Cassidy, Environment, Clinical Laboratory, Liquid biopsy, Center, Pathology, Solution, Pharmaceutical industry, Medical imaging, Medicine

Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that their San Diego-based clinical laboratory received accreditation by the College of American Pathologists (CAP).

Key Points: 
  • Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that their San Diego-based clinical laboratory received accreditation by the College of American Pathologists (CAP).
  • This achievement follows the recent certification under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 from the U.S. Department of Health and Human Services Centers for Medicare and Medicaid Services.
  • The CAP Laboratory Accreditation Program is the gold standard for laboratory excellence.
  • CLIA certification confirms that Nucleixs clinical laboratory meets the federal regulations for clinical diagnostic testing, ensuring high quality and safety for patient testing.

GRAIL and Carrum Health Partner to Include Galleri® as Part of Comprehensive Cancer Care Offering to Employers

Retrieved on: 
Thursday, October 13, 2022
Biotechnology, General Health, Health, Clinical Trials, Oncology, Adoption, Gene expression, Prostate-specific antigen, CLIA, College of American Pathologists, Risk, Diagnosis, Machine learning, Illumina, Inc., List of pathologists, American Joint Committee on Cancer, Genomics, Algorithm, NASDAQ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, LLC, Excellent, Program, Colonoscopy, Methylation, Partnership, Cancer, Technology, Solution, Food, Center, Trial of the century, Tiger Global Management, CEO, Cervical cancer, Ageing, College, Clinical trial, United Kingdom, Clinical Laboratory, Silicon, DNA, European Commission, Digital, PSA, COE, Mammography, Health insurance, Medical imaging, GRAIL, The McLoughlin Gallery

This product integration will enable employers who offer Carrum Health benefits to provide eligible employees the Galleri test as part of the comprehensive cancer care Carrum delivers.

Key Points: 
  • This product integration will enable employers who offer Carrum Health benefits to provide eligible employees the Galleri test as part of the comprehensive cancer care Carrum delivers.
  • GRAILs early cancer detection test is a critical component in a comprehensive oncology offering and were thrilled to extend this benefit to Carrum members.
  • We are proud to partner with Carrum Health, who shares our commitment to transforming cancer care and reducing rising healthcare costs.
  • Members who receive a signal detected from the Galleri test can work with a Carrum Health COE for diagnostic evaluation and guideline-concordant treatment planning.

Proscia Releases New Version Of Concentriq Dx Enabling Laboratories To Achieve 100% Digital Diagnosis

Retrieved on: 
Wednesday, October 12, 2022
Dark, Adoption, Laboratory, Digital Pathology Association, Occupational burnout, Hospital, Pathology, Diagnosis, List of pathologists, Patient, IVDR, Research, Medical laboratory, Cancer, University, MD, Department, S, Health, Hospital of the University of Pennsylvania, Marie Cassidy, COVID-19, Solution, Public health, Medical device, Pharmaceutical industry, Medical imaging

PHILADELPHIA, Oct. 12, 2022 /PRNewswire-PRWeb/ -- Proscia®, a leading provider of digital and computational pathology solutions, has introduced the next version of its Concentriq® Dx platform for primary diagnostic workflows, which is CE-marked under IVDR*. The release brings together new features and a compelling user experience to help even the largest laboratory networks transition to 100% digital diagnosis. In doing so, they can realize the full promise of the shift away from microscope-based pathology.

Key Points: 
  • The release brings together new features and a compelling user experience to help even the largest laboratory networks transition to 100% digital diagnosis.
  • Trusted by top laboratories and health systems, Concentriq Dx is a secure, AI-ready digital pathology platform that powers primary diagnostic workflows.
  • To learn more about Concentriq Dx and see a demo, visit Proscia at booth 315 during Pathology Visions, the Digital Pathology Association's annual meeting.
  • *Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency.

Sampled SMART Labs Expands its New Jersey Footprint

Retrieved on: 
Tuesday, October 11, 2022
Biotechnology, General Health, Health, Other Health, CAP, Biophysical environment, Communication, CLIA, Growth, Transport, List of pathologists, LLC, Genomics, SMART, Research, PerkinElmer, Multimedia, Abraxis BioScience, Collection, Certification, International Society for Biological and Environmental Repositories, International Society, Industry, Health, LN2, College, Thermo Fisher Scientific, Biology, Rutgers University, Television, Fine chemical, Architecture, Illumina, Sample

Sampled1 has announced the expansion of its Sampled SMART Labs facility into a state-of-the-art, 140,000 square foot laboratory and biorepository in Piscataway, NJ.

Key Points: 
  • Sampled1 has announced the expansion of its Sampled SMART Labs facility into a state-of-the-art, 140,000 square foot laboratory and biorepository in Piscataway, NJ.
  • Sampled SMART Labs have CAP (College of American Pathologists) and CLIA (Clinical Laboratory Improvement Amendments) certification and adhere to ISBER (International Society for Biological and Environmental Repositories) best practices.
  • We are thrilled that Sampled SMART Labs is expanding its industry and deepening its investment in Piscataway, said Brian C. Wahler, Mayor of Piscataway.
  • Sampled is headquartered in Piscataway, N.J. with labs across the US and Europe and partner labs in the Netherlands, China and Australia.

College of American Pathologists Honors 22 Members/Residents at CAP22 Annual Meeting

Retrieved on: 
Sunday, October 9, 2022
Education, Health, Infectious Diseases, COVID-19, Research, Science, University, CAP, Racism, Alpha and Omega, American College of Obstetricians and Gynecologists, Georgia Association of Educators, List of pathologists, Education, Phi Beta Kappa, Patient, Council, Department, Association, CEO, Health, College, Marie Cassidy, Social justice, Government, Gynaecology, American College, COVID-19, Â, Hospital, Pathology, MD

During his 30 years as a CAP member, Dr. Godbey served two full terms as a member of the CAP Board of Governors.

Key Points: 
  • During his 30 years as a CAP member, Dr. Godbey served two full terms as a member of the CAP Board of Governors.
  • So many pathologists immediately took up the fight against COVID-19 and we much more than answered the call, Dr. Godbey comments.
  • Further, Dr. Godbey conceived and helped direct the pathologists pipeline initiative, working to introduce the pathology specialty to more medical students.
  • The CAP annually honors members for their commitment to the specialty and quality patient care.

Global Molecular Quality Controls Market Report 2022: Increasing Number of Accredited Clinical Laboratories Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 4, 2022
Health, Biotechnology, Cancer, ISO, Incidence, RAD, Diagnosis, University of California, Berkeley, List of pathologists, Disease, Industry, Compliance, International Organization for Standardization, CAGR, Down syndrome, Projection, FDA, International Organization (journal), Quality control in tissue engineering, Revenue, Infection, Genetic testing, Growth, Bio-Rad Laboratories, College of American Pathologists, Genomics, Lists of diseases, College, Accreditation, USD, Application, Breast cancer, Anomaly, Technology, Awareness, Medical device, Vaccine, Telecommunication

The global molecular quality controls market size is expected to reach USD 294.31 million by 2030.

Key Points: 
  • The global molecular quality controls market size is expected to reach USD 294.31 million by 2030.
  • Trends in the industry are driven by several variables, including the steadily rising number of clinical laboratories that are accredited.
  • Today, clinical laboratories all around the world are vying for national and international accreditation, largely to guarantee more dependable and superior laboratory services.
  • Molecular Quality Controls, Product Outlook (Revenue - USD Million, 2018 - 2030)
    Molecular Quality Controls, Technology Outlook (Revenue - USD Million, 2018 - 2030)